| 영문 | acetylcholine | 한글 | 아세틸콜린 |
|---|---|---|---|
| 설명 | 신경전달물질의 한 가지. 근육을 지배하는 신경의 말단에서 분비되어 근육의 수축을 유도하기도 하며, 부교감신경의 말단에서 분비되어 부교감신경의 전달을 담당하기도 하고, 뇌의 신경세포에서도 분비되어 여러 가지 작용을 한다. |
||
| misc | miscarriage; miscellaneous |
|---|---|
| brom | bromide |
| CPB | carboxypeptidase B; cardiopulmonary bypass; cetylpyridinium bromide; competitive protein binding |
| CTAB | cetyltrimethyl-ammonium bromide |
| FAB | fast atom bombardment; formalin ammonium bromide; fragment, antigen-binding [of immunoglobulins]; Fr... |
| ACh | 14C)acetylcholine |
|---|---|
| [(3)H]-ACh | 3)H]-acetylcholine |
| AcCh | Acetylcholine |
| AcCho | Acetylcholine |
| AChR | Acetylcholine Receptor |
| acetylcholine | <chemical, neurology, physiology> A chemical found in vertebrate neurons that carries information across the synaptic cleft, the space between two nerve cells. (06 May 1997) |
|---|---|
| acetylcholine chloride | A miotic, administered as an ophthalmic solution for parasympathomimetic effect; used in cataract surgery. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| muscarinic acetylcholine receptor | Distinct from the nicotinic ACh receptor in having no intrinsic ion channel, the receptor is formed from one protein chain with 7 transmembrane regions. The receptors produce their effect via activation of GTP-binding proteins. (18 Nov 1997) |
| nicotinic acetylcholine receptor | Integral membrane protein of the postsynaptic membrane to which acetylcholine binds. The receptor contains an integral ion channel, as a result of binding of acetylcholine, ion channels in the subsynaptic membrane are opened. at the neuromuscular junction, the nicotinic acetylcholine receptor initiates muscle contraction. Currently the best characterised ion channel protein: made of a hetero pentamer of related subunits, although a homo pentamer is functional in insects. Structural studies show that the acetylcholine binding site and the ionic channel are part of the same macromolecular unit. The nAChR mediates rapid transduction events (1ms) whereas receptors activating G-protein coupled channels operate on slower time scales (millisecond to second range). (18 Nov 1997) |
| ammonium bromide | A sedative. (05 Mar 2000) |
| azamethonium bromide | A ganglionic blocking agent. Chemical name: [(Methylimino)diethylene]bis-[ethyldimethylammonium bromide]. (05 Mar 2000) |
| benzpyrinium bromide | 1-benzyl-3-hydroxypyridinium bromide diethylcarbamate;a cholinergic drug with action and uses similar to those of neostigmine. Synonym: benzstigminum bromidum. (05 Mar 2000) |
| bromide | <chemistry> A compound of bromine with a positive radical. Source: Websters Dictionary (01 Mar 1998) |
| bromide acne | Follicular eruption on face, trunk, and extremities, due to bromide ingestion. See: bromoderma. (05 Mar 2000) |
| butylscopolammonium bromide | <chemical> Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract. Pharmacological action: muscarinic antagonists, parasympatholytics. Chemical name: 3-Oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))- (12 Dec 1998) |
| calcium bromide | Used to meet the same indications as potassium bromide. (05 Mar 2000) |
| valethamate bromide | 2-Diethylaminoethyl 3-methyl-2-phenylvalerate methylbromide;an anticholinergic agent. (05 Mar 2000) |
| pancuronium bromide | 2b,16b-Dipiperidino-5a-androstane-3a,17b-diol diacetate dimethobromide;a nondepolarising steroidal neuromuscular blocking agent resembling curare but without its potential for ganglionic blockade, histamine release, or hypotension. (05 Mar 2000) |
| vecuronium bromide | <chemical> Monoquaternary homolog of pancuronium. A non-depolarising neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. Pharmacological action: neuromuscular nondepolarising agents, nicotinic antagonists. Chemical name: Piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl)-1-methyl-, bromide (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|